Biotechnology

BioTech Medics Continues to Execute Its Calcium Business Plans

November 20, 2023 9:00 AM

WOODLAND HILLS, CA / ACCESSWIRE / November 20, 2023 / BioTech Medics, Inc. (OTC PINK:BMCS) is pleased to announce that the Company continues to build the fundamental substructure that will enhance our ability to raise capital to position the organization in a competitive advantage with its calcium carbonate assets to enhance BMCS as a substantial publicly traded firm in this sector. Our website can be found at www.biotechmedics.co According to...

Read more

Biophytis Announces Receipt of Nasdaq Notice

November 17, 2023 5:15 PM

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / November 17, 2023 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related neuromuscular and respiratory diseases, today announced...

Read more

Tharimmune Announces 1-for-25 Reverse Stock Split

November 17, 2023 7:00 AM

BRIDGEWATER, NJ / ACCESSWIRE / November 17, 2023 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic conditions announced today that it will effect a 1-for-25 reverse stock split of its issued and outstanding shares of common stock. The reverse stock split was previously approved by Tharimmune stockholders...

Read more

enVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium

November 16, 2023 8:45 AM

No Deaths or Pulmonary Embolisms Occurring During the 30 Day MAE Period Expected Overall Device-Related Material Adverse Event Rate of 8% for the Fully Enrolled 75 Patient Study Six (6) DVT Related MAEs IRVINE, CA / ACCESSWIRE / November 16, 2023 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that positive preliminary device...

Read more

The Largest Biotech City in Europe Will Soon Be Built, With an Investment Amounting to 7 Billion Euros

November 16, 2023 8:20 AM

VILNIUS, LITHUANIA / ACCESSWIRE / November 16, 2023 / Northway Group is embarking on a project to establish Europe's largest biotechnology hub, BIO CITY, in Vilnius, the capital of Lithuania. It includes 6 large biotechnological complexes - 4 state-of-the-art GMP manufacturing plants and 2 advanced scientific research centres - that will be built in an area equivalent to 10 football fields. The total investment for this biotech campus is...

Read more

Ensysce Biosciences Announces Enrollment Completion for PF614-201 Clinical Study

November 16, 2023 8:15 AM

~ Enrollment Completion Signifies Critical Progress to Phase 3 of PF614 ~ ~ Trial Results Expected in December 2023 ~ SAN DIEGO, CA / ACCESSWIRE / November 16, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that the PF614-201 study, ‘A Randomized, Double-Blind, Placebo-Controlled Crossover Study of PF614...

Read more

Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols

November 16, 2023 8:00 AM

- DMT310 Phase 3 STAR-1 (Spongilla Treatment of Acne Research) clinical trial will evaluate the efficacy and safety of once-weekly treatments of DMT310 for 12 weeks in moderate-to-severe acne patients - - Topline results from STAR-1 clinical trial expected in Q1 2025 - - DMT310, if approved, may be the first once-weekly, topical acne treatment - SAN DIEGO, CA / ACCESSWIRE / November 16, 2023 / Dermata Therapeutics, Inc....

Read more

Ondine Biomedical Inc Announces Photodisinfection Recommended as Standard of Care

November 16, 2023 2:40 AM

Peer-reviewed publication involving 13,493 patients reports 66.5% decrease in spine surgery infection rate sustained over 8 years with the use of Steriwave® nasal photodisinfection VANCOUVER, BC / ACCESSWIRE / November 16, 2023 / Canadian life sciences company, Ondine Biomedical Inc. (LSE:OBI), reports that an independent, peer-reviewed research paper, "Effectiveness of prophylactic intranasal photodynamic disinfection therapy and chlorhexidine...

Read more

GeneTex Augments Its GPCR Reagent Portfolio With a Highly Specific CXCR2 Recombinant Monoclonal Antibody

November 15, 2023 9:00 AM

IRVINE, CA / ACCESSWIRE / November 15, 2023 / GeneTex, a multinational antibody manufacturer, announces a new addition to its growing product line of validated recombinant monoclonal antibodies against G protein-coupled receptors (GPCRs). CXC motif chemokine receptor 2 (CXCR2) belongs to the family of 20 human chemokine receptors responsible for signal transduction triggered by the binding of one or more of 46 chemokines. Chemokines and their...

Read more

Altius Bioventures Initiates Fundraising for Altius Bioventures Fund I

November 15, 2023 9:00 AM

VANCOUVER, BC / ACCESSWIRE / November 14, 2023 / Altius Bioventures, has launched a fundraising campaign for Altius Bioventures Fund I, targeting a total raise of US$20 million, with an initial close of US$10 million. Altius Bioventures Fund I, in conjunction with its connected accelerator program, Altius Bioventures Racer, will focus on investing in and building early-stage companies aimed at delivering transformative technologies, tools and...

Read more

MRES: M2Bio Sciences Expands Global Presence with New Offices in Dubai Science Park

November 15, 2023 6:30 AM

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / November 15, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES): A pioneering force in nutraceutical biotechnology, specializing in alternative plant-based cannabinoids, medical psilocybin, and avant-garde mental health therapeutic research driven by artificial intelligence (AI), is delighted to share a significant update: M2Bio Sciences Embarks on Strategic Expansion into Dubai Science Park...

Read more

Hemogenyx Pharmaceuticals PLC Announces Lentivirus Re-manufacturing Completed

November 15, 2023 2:00 AM

Lentivirus Re-manufacturing Completed LONDON, UK / ACCESSWIRE / November 15, 2023 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce the successful completion of the re-manufacturing of an improved lentivirus ("LVV") devoid of splice variants. The LVV is used to programme the Company's Chimeric Antigen Receptor ("CAR") T-cells ("HEMO-CAR-T")...

Read more

Vaso Corporation Announces Financial Results for Third Quarter 2023

November 14, 2023 9:22 AM

Making it the sixth consecutive quarter of profitability PLAINVIEW, NY / ACCESSWIRE / November 14, 2023 / Vaso Corporation ("Vaso") (OTCQX:VASO) today reported its operating results for the three months ended September 30, 2023. "For the third quarter of 2023, the Company's revenue was $19.4 million, compared to the prior year's third quarter revenue of $19.8 million. The slight decrease in revenue was mainly due to lower deliveries of...

Read more

Brainify.AI and Clerkenwell Health Announce Strategic Partnership to Propel Precision Psychiatry Forward

November 14, 2023 9:00 AM

NEW YORK, NY / ACCESSWIRE / November 14, 2023 / Brainify.AI, a trailblazer in artificial intelligence EEG biomarkers, and Clerkenwell Health, a modern mental health research company specializing in matching patients with cutting-edge psychiatry treatments, today unveiled a partnership poised to revolutionize the psychiatric clinical trial landscape. This trans-Atlantic partnership marks a significant step toward the implementation of precision...

Read more

MRES: M2Bio Sciences Marks Milestone Expansion with Launch of Los Angeles Office

November 14, 2023 8:00 AM

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / November 14, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to provide the following update: M2Bio Sciences Food & Beverage strategically expands...

Read more

MBQ Pharma announces the First-in-Human Dose for Advanced Breast Cancer with the dual targeted Rac/Cdc42 inhibitor: MBQ-167

November 13, 2023 3:30 PM

MBQ-167 is a first-in-class small molecule and dual targeted inhibitor of over-expression of two proteins (Rac and Cdc42) that enable cancer metastasis and increased resistance to other anti-cancer agents. 90% of cancer-related deaths are related to cancer metastasis and MBQ-167 is being evaluated in this first human clinical trial to determine the best dose to evaluate this investigational drug in future studies to determine its safety and...

Read more

FluoGuide Announces FG001 Meets Primary Endpoint in Phase llb Trial in Aggressive Brain Cancer

November 13, 2023 2:50 AM

All patients (12/12) receiving FG001 had additional cancer detected by optical guidance FG001 was safe and well tolerated in all patients KØBENHAVN, DENMARK / ACCESSWIRE / November 13, 2023 / FluoGuide A/S (STO:FLUO) FluoGuide A/S ("FluoGuide" or the "Company"), a pioneer in the cutting-edge field of precision cancer surgery, today announced positive topline efficacy and safety results in the phase IIb trial with the lead product FG001 for...

Read more

Biovica Signs Commercial Partner for the DiviTum(R) TKa Assay in the Nordics

November 13, 2023 2:20 AM

UPPSALA, SE / ACCESSWIRE / November 13, 2023 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Today, Biovica, active in cancer monitoring, announces that the company has signed a commercial partnership agreement for the Nordics with Axlab A/S to commercialize the DiviTum® TKa assay. "Axlab is a top-5 brand in cancer screening and diagnostics in the Nordics and has delivered impressive sales results. We are excited to sign an...

Read more

NovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory Board

November 10, 2023 9:00 AM

CLEVELAND, OH / ACCESSWIRE / November 10, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a preclinical biomedical company developing novel immunotherapies for brain tumor patients, today announced the appointment of Dr. Roscoe M. Moore, Jr., to its Scientific Advisory Board. Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service (USPHS) entering with the U.S. National Institutes of Health (NIH) and...

Read more

Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results

November 10, 2023 8:35 AM

Encouraging growing body of preclinical data guiding pathway to first in human trial for DNase-based oncology platform Driving development towards Phase 1 program for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Continuing partnering discussions to advance development of systemic DNase and DNase-Armored CAR T programs Ended the quarter with $9.8 million of cash to fund operations FRAMINGHAM, MA /...

Read more